InvestWiser

XSpray Pharma AB

XSPRAYNasdaq StockholmHealthcareMarket value 542 m SEK
10.90SEK −0.4%
last day · Price as of 18 November 2026

The answer first

Does XSpray Pharma beat the market?

No, XSpray Pharma has not beaten the market over the last year.

XSpray Pharma−55.3%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 23% of Nordic stocks

    • Quality71
    • Value18
    • Trend22

    No. 123 of 195 in healthcare

Max for seven days

Follow XSpray Pharma with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on XSpray Pharma

From today, at a price of 10.90 SEK. Write why you follow XSpray Pharma, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about XSpray Pharma

Your first answer is free, no account needed.

Do you own XSpray Pharma, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with XSpray Pharma and a few more. Free, no card.

Past year against the exchange and Super Stock
XSpray Pharma−55.3%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • XSpray Pharma has fallen 55.3% over the past year, including dividends.
  • Overall, XSpray Pharma ranks better than 23% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 89.0%. The price is 95.5% below its peak now.

What do analysts think of XSpray Pharma?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

23

Quality, value and trend together. Better than 23% of Nordic stocks.

No. 123 of 195 in healthcare

Quality71
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 82 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.41
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−25.3%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value18
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 107 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.9
  • P/SPrice divided by sales82.1
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend22
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 119 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+4.2%
  • 6 months−54.8%
  • 9 months−58.2%
  • 12 months−55.3%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−0.5%
3 years, per year
−32.6%
5 years, per year
−31.6%
Year to date
−64.4%
Largest fall, 3 years
−89.0%
From a peak to the bottom
From the peak now
−95.5%
How far the price is from the peak
Volatility, 1 year
77.3%
How much the price swings over a year
Beta, 1 year
0.97
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own XSpray Pharma

4 funds we follow own XSpray Pharma. The share is how much of the fund the stock makes up.

  • Sweden4

From the funds' latest known holdings.

About XSpray Pharma

XSpray Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 24 employees.

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc.

See the full analysis of XSpray Pharma.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market